Under the Paperwork Reduction Act of 1995, no persons are required to respon

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	
( Not for submission under 37 CFR 1.99)	

Application Number		10564533				
Filing Date		2006-01-12				
First Named Inventor Johan		nnis F R BLACQUIERE, ET AL				
Art Unit		2627				
Examiner Name						
Attorney Docket Number		NI 030903				

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Kind Code1 Issue Date		ntee or Applicant Relevan		s,Columns,Lines where vant Passages or Releva es Appear			
	1										
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ition	of sited Desument		Releva	Columns, nt Passaç Appear	Lines where ges or Relev	ant
	1	20030031106	A1	2003-02	!-13	OZAKI					
	2	20010038704	A1	2001-11	1-08	LTO					
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d button	Add		
				FOREIG	3N PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>		Name of Patente Applicant of cited Document	e or V	vhere Rel	or Relevant	76
	1	0730274	EP		A2	1996-09-04	INCAT SYSTEMS	USA			Г
	2	02086729	wo		A2	2002-10-31	KPENV				С

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10564533			
Filing Date		2006-01-12			
First Named Inventor Johan		nnis F R BLACQUIERE, ET AL			
Art Unit		2627			
Examiner Name					
Attorney Docket Number		NL030903			

	3	03012780	wo	A2	2003-02-13	ENTERPRISE CORP				
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove			
Examiner Initials*	Examiner Cite Initials* No (blook, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									
	1	GCC C++ - GNU Project C, and C++ Compiler								
	2	ISR for Publication, Informational Publication Number WC2005/008690								
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE										
Examiner Signature Date Considered										
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

See Kind Codes of USPTO Patent Documents at Invest, ISEPTO\_GOLy or MPEP 901.04. 2 Enter of this that issued the document, by the Involved or (WIPO) Standard ST3.) 3 For Suppresse patent documents, the indication of the parent of the register or interpreted the serial results of the Empirer or may precede the serial results of the Empirer or may precede the serial results of the Empirer or may be received by the appropriate symbols as endicated on the document under WIPO Standard ST.16 if possible, 2 Applicant is to place a check mark here if Empirel Instrume translation is attracted.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10564533		
Filing Date		2006-01-12		
First Named Inventor Johan		nis F R BLACQUIERE, ET AL		
Art Unit		2627		
Examiner Name				
Attorney Docket Number		NL030903		

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.9	to make the	appropr	iate selection(s):
---------------	----------	---------	-------------	---------	--------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(4)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torn or the signature.							
	Signature	/Michael E. Belk/	Date (YYYY-MM-DD)	2007-03-19			
	Name/Print	Michael F Relk	Registration Number	33.357			

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 122 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2213-1450, D. ON TO SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2213-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.